Objective: To describe survival patterns in a nationally complete cohort of Australian women with epithelial ovarian cancer, by sociodemographic and clinical factors.
O varian cancer is the seventh most common cause of cancer mortality in Australian wo men, accounting for an estimated 1080 deaths in 2013, 1 but there are no comprehensive national data describing clinical and non-clinical factors associated with survival in Australian women. Available information is derived from cancer registries, 1,2 which hold little or no information on important prognostic factors like stage of disease, or is state-specifi c and not contemporary. 2, 3 Furthermore, estimates of conditional survival, which take into account time already survived and are of practical value to clinicians and patients, 4 are not available in the Australian context.
We used data from a complete national cohort of women diagnosed with invasive epithelial ovarian cancer in Australia in 2005 to describe survival patterns by sociodemographic, clinical and histopathological features, and to calculate conditional survival estimates.
Methods
In 2009, the Australian state-and territory-based cancer registries identifi ed all women aged у 18 years who had been diagnosed with primary invasive epithelial ovarian cancer (including fallopian tube and primary peritoneal cancers) in Australia during 2005. We obtained de-identifi ed clinical information from all the women's medical records. Cancer registries also provided women's ages and postcodes at diagnosis and, where available, the grade and histological subtype of their cancers. 5 The study was approved by the human research ethics committees of the QIMR Berghofer Medical Research Institute and all participating institutions.
Participant characteristics
Postcode was used to classify women's area of residence using the Accessibility/Remoteness Index of Australia (ARIA+). 6 We further categorised women as being from major cities or regional-remote areas. We also used postcode as a measure of socio economic status using the Index of Relative Socio-Economic Advantage/Disadvantage, one of the Socio-Economic Indexes for Areas (SEIFA), 7 which is based on indicators including income and skilled employment. We categorised women as relatively disadvantaged or advantaged by dividing their SEIFA scores at the median. Medical record information was used to derive comorbidity scores based on the Charlson comorbidity index, 8 with a higher score indicating a larger number or greater severity of comorbidities. Scores were grouped for analysis (0, 1, 2 or у 3).
Cancer characteristics
Histological subtype was classifi ed as serous, mucinous, endometrioid, clear cell or carcinosarcoma; and tumour grade as well differentiated, moderately differentiated or poorly differentiated. Information on stage, according to the International Federation of Gynecology and Obstetrics (FIGO) 1988 system, was abstracted from clinical notes. Women for whom stage information was missing were classifi ed as having advanced disease (called stage III/ IV) if they met any of the following criteria: macroscopic residual disease; poorly differentiated cancer with serous subtype; or poorly differentiated cancer without surgical intervention. Women missing data for other cancer characteristics were included in a separate category in our analyses. However, inclusion of women missing subtype data resulted in violation of proportional hazards assumptions and thus we excluded this group from subtype analyses.
Survival data
As specifi c cause-of-death information was not available for all women, the outcome was death from any cause. However, among women with this information, over 95% of deaths were from ovarian cancer. We obtained death information from medical records in 2009, and updated data were obtained from the cancer registries in 2012. The New South Wales cancer registry was unable to provide the updated information. However, a third of the women in our study also participated in the Australian Ovarian Cancer Study, 9 and death information for these women was available until October 2011 through linkage to the National Death Index. Thus, we still had complete 5-year survival information for 74% of women from NSW. Participants not known to have died were censored at the last date of data linkage. Survival time was calculated from date of diagnosis until death or censoring.
Statistical analysis
We estimated crude 3-year, 5-year and 7-year survival rates with 95% confi dence intervals (CIs) using the Kaplan-Meier method. If S(t) is taken as the traditional survival at time t, then CS, conditional survival, is the probability of surviving an additional y years, given that an individual has already survived x years, and is expressed as: CS(y|x) = S(x + y)/S(x). 4 We calculated 3-year and 5-year conditional survival probabilities for women who had already survived 1 and 2 years; and, additionally, 3-year conditional survival for those who had survived 3 years. We calculated hazard ratios (HRs) and 95% CIs for the association of participant and cancer characteristics with survival using multivariable Cox proportional hazards models. Proportional hazards assumptions were tested using scaled Schoenfeld residuals. Analyses were conducted using Stata, version 11.2 (Stata Corporation).
Results
During 2005, 1192 women were registered with a diagnosis of invasive epithelial ovarian, fallopian tube or primary peritoneal cancer. The women's mean age was 65 years (SD, 13 years), and 71% were from major cities. Most (69%) had stage III or IV cancer, and 43% had ascites. More than half the cancers (53%) were serous subtype, and 61% were poorly differentiated (Box 1).
Stage information was not available for 283 women, most of whom did not have surgery. We classifi ed 149 of these women (13%) as having stage III/IV disease. The proportion of data missing for other cancer characteristics ranged from 16% to 24%.
Box 2 shows Kaplan-Meier survival curves for the women by age, FIGO stage, socioeconomic status and area of residence. Box 1 shows 3-year, 5-year and 7-year survival and HRs by participant and cancer characteristics. Advanced age was associated with worse survival. This was mostly explained by stage and comorbidity score but, even after adjustment for these, age remained signifi cantly associated with survival (HR adj , 1.3 [95% CI, 1.2-1.4] for each 10-year increment).
The rate of death of women with stage IV disease was 10 times that of women with stage I disease (HR adj , 10.2 [95% CI, 6.5-16.1]). After adjusting for other variables, especially stage, the effect estimates associated with grade attenuated and were no longer statistically signifi cant (HR adj , 1.5 [95% CI, 0.9-2.5] for moderately differentiated and HR adj , 1.4 [95% CI, 0.9-2.4] for poorly differentiated v well differentiated cancers). We explored this relationship further by stage. Among women with stage I or II disease, the HRs associated with grade were 3.2 (95% CI, 0.9-11.3) for poorly differentiated and 1.7 (95% CI, 0.4-6.6) for moderately differentiated cancers; while among women with advanced disease, the HRs were 1.6 (95% CI, 0.9-2.7) and 1.5 (95% CI, 0.9-2.7) for poorly and moderately differentiated cancers, respectively. The interaction term for stage and grade was not, however, statistically signifi cant.
In age-adjusted analyses, mucinous, endometrioid and clear cell subtypes were associated with better survival than serous cancers. Higher comorbidity scores were modestly associated with survival, as was socioeconomic status (Box 1). Compared with women from relatively socioeconomically advantaged areas, women from relatively disadvantaged areas had a 21% higher risk of dying during follow-up. A similar difference was seen for women living in regional-remote areas versus major cities. There were no signifi cant survival differences by state after adjustment.
Box 3 shows conditional survival for women who survived up to at least 3 years after diagnosis. Threeyear conditional survival was 47% at diagnosis; however, for those who did survive 3 years from diagnosis, the probability of surviving a further 3 years increased to 68% (95% CI, 64%-72%). The 5-year conditional survival rates increased from 35% at diagnosis to 53% (95% CI, 49%-57%) for women who survived 2 years. In general, the greatest increases in conditional survival were seen in groups with the lowest survival probabilities at diagnosis.
Discussion
In this national cohort of women with epithelial ovarian cancer, increasing age and disease stage were the factors most strongly associated with poorer survival. In addition, we found significant independent associations with ascites, comorbidities, and regionalremote and relatively disadvantaged areas of residence. Overall survival was poor, with just over a third of women (35%) surviving 5 years from diagnosis. For women who survived ACT = Australian Capital Territory. NT = Northern Territory. * Percentages may not sum to 100% because of rounding. † Adjusted for age at diagnosis, comorbidity score, stage, grade, subtype and presence of ascites. Analysis by state was also adjusted for socioeconomic status and area of residence. ‡ Women with missing stage information were classifi ed as having stage III/IV disease if they met any of the following criteria: macroscopic residual disease; poorly diff erentiated cancer with no surgery; poorly diff erentiated cancer of serous subtype. § HR could not be calculated due to violation of proportional hazards assumption. ¶ Weighted score based on the Charlson comorbidity index. ** Estimate could not be calculated due to incomplete 7-year survival data. † † Estimates are imprecise due to small number of women diagnosed with ovarian cancer in Tasmania in 2005.   beyond 1, 2 or 3 years, subsequent 3-year and 5-year survival increased moderately, although 5-year conditional survival at 2 years was still only 53%.
It is important to note that our survival rates are crude and, while they refl ect the actual survival for this group, they do not take into account the probability of death from other causes and cannot be used for international comparisons. Contemporary routine Australian statistics suggest a relative 5-year survival rate of about 43%, 1 which compares favourably with estimates for similar periods from other Organisation for Economic Co-operation and Development countries (Box 4).
Our fi ndings are comparable to international studies showing that stage is the most important predictor of survival. [15] [16] [17] Similar to some reports, 15, 16 we found that after adjusting for stage, cancer grade had limited independent prognostic signifi cance. In contrast, other studies 3, 17 found that higher grade remained signifi cantly associated with survival after adjusting for stage. There can be considerable intra-and inter-observer variability in determining ovarian cancer grade, 18 which might explain these confl icting results. However, our results also suggest that the effect of grade may be modifi ed by stage, such that higher grade is most relevant to survival in women with early-stage cancers.
Similar to others, 19 we found that women with carcinosarcomas had the poorest survival, possibly refl ecting aggressive tumour biology or less sensitivity to routinely used chemotherapy. 20 We also found differences for women with mucinous and clear cell cancers. These women mostly presented with early-stage disease (data not shown), but our results suggest that for cancers of equivalent stage, survival is worse for women with these subtypes compared with serous cancers. This may refl ect the poorer response of mucinous and clear cell cancers to conventional platinum and paclitaxel-based chemotherapy 21, 22 and reinforces the need for new treatments for these cancer subtypes. Consistent with other work, 23 we also found a 50% greater risk of mortality in women with ascites at diagnosis, underscoring the importance of ongoing clinical trials aimed at improving outcomes in these patients.
Age was an important predictor of survival in our analyses, with women aged у 70 years having a two-to threefold greater risk of death during follow-up. Older women in this cohort were less likely to receive standard chemotherapy, 5 so this and other age-related treatment variations may be affecting survival times for older women.
The association between prediagnosis comorbidities and survival among women with ovarian cancer is inconsistent in the literature. 24, 25 Our results suggest that women with multiple or severe comorbidities do worse. As the type and severity of comorbid diseases affect treatment decisions, some of this effect may be mediated by treatment received.
While it is recognised that cancer mortality is generally higher in socioeconomically disadvantaged and regional-remote areas of Australia, 1,26,27 previous studies have not clearly shown these associations with ovarian cancer survival. 1,2,27 Our analyses suggest a modest effect of area of residence. We considered the possibility that this might be due to higher rates of deaths from other causes but, among the women for whom we had cause-of-death data, there was no difference in percentage of deaths due to ovarian cancer by area of residence. Possible explanations for socioeconomic and geographic differences in ovarian cancer survival include diagnostic delay and poorer access to recommended treatments. 27 Further research is needed to determine the relative contribution of these factors.
Strengths of our study include the large national sample, the comprehensive data collection and completeness of follow-up. To our knowledge, this is also the fi rst study to provide national conditional survival estimates for ovarian cancer in Australia. Conditional survival information can be used to communicate prognosis to patients and their families more accurately along their disease journey. Our estimates confi rm the ongoing poor prognosis of the disease and emphasise the need for primary and secondary prevention and better treatments for ovarian cancer to improve long-term outcomes.
In conclusion, this study of all women diagnosed with invasive epithelial ovarian cancer in Australia in 2005 provides population-level evidence on factors that infl uence 
